title: Astragalus in the prevention of upper respiratory tract infection in children with nephrotic syndrome: evidence-based clinical practice.
abstract: Aims. To explore whether Astragalus or its formulations could prevent upper respiratory infection in children with nephrotic syndrome and how best to use it. Methods. We transformed a common clinical question in practice to an answerable question according to the PICO principle. Databases, including the Cochrane Library (Issue 5, 2012), PUBMED (1966-2012.8), CBM (1978-2012.8), VIP (1989-2012.8), and CNKI (1979-2012.8), were searched to identify Cochrane systematic reviews and clinical trials. Then, the quality of and recommendations from the clinical evidence were evaluated using the GRADEpro software. Results. The search yielded 537 papers. Only two studies with high validity were included for synthesis calculations. The results showed that Astragalus granules could effectively reduce URTI in children with nephrotic syndrome compared with prednisone treatment alone (23.9% versus 42.9%; RR = 0.56 and 95% CI = 0.33-0.93). The dose of Astragalus granules was 2.25 gram (equivalent to 15 gram crude Astragalus) twice per day, at least for 3-6 months. The level of evidence quality was low, but we still recommended the evidence to the patient according to GRADEpro with the opinion of the expert. Followup showed the incidence of URTI in this child decreased significantly. Conclusions. Astragalus granules may reduce the incidence of URTI in children with nephrotic syndrome.
authors: Nephrology Center, Guangdong Provincial Hospital of Chinese Medicine, No. 111 Dade Road, Guangzhou, Guangdong Province 510120, China.
authors: Chuan
authors: C
authors: Zou
authors: Guobin
authors: G
authors: Su
authors: Yuchi
authors: Y
authors: Wu
authors: Fuhua
authors: F
authors: Lu
authors: Wei
authors: W
authors: Mao
authors: Xusheng
authors: X
authors: Liu
references: Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003964
references: 22513919
references: Pediatrics. 1984 Apr;73(4):497-501
references: 6709428
references: Evid Based Complement Alternat Med. 2006 Dec;3(4):459-67
references: 17173109
references: Clin Pediatr (Phila). 2002 Jan-Feb;41(1):47-9
references: 11866366
references: BMJ. 1999 Jul 17;319(7203):160-1
references: 10406751
references: Arch Dis Child. 1960 Apr;35:115-26
references: 14414748
references: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006335
references: 18425948
references: Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Nov;38(6):969-72
references: 18095598
references: Altern Med Rev. 1998 Dec;3(6):422-31
references: 9855567
references: Pediatr Res. 1977 Aug;11(8):910-6
references: 407543
references: Pediatrics. 1982 Feb;69(2):219-23
references: 7058096
references: J Med Assoc Thai. 2005 Nov;88 Suppl 8:S142-8
references: 16856434
references: Integr Cancer Ther. 2003 Sep;2(3):247-67
references: 15035888
references: J Clin Epidemiol. 2013 Feb;66(2):140-50
references: 22863410
references: BMJ. 2008 May 10;336(7652):1049-51
references: 18467413
references: Immunopharmacology. 1990 Nov-Dec;20(3):225-33
references: 2149722
references: J Clin Lab Immunol. 1988 Mar;25(3):125-9
references: 3260961
references: Arch Dis Child. 2008 Mar;93(3):226-8
references: 17573408
references: J Paediatr Child Health. 1998 Aug;34(4):314-7
references: 9727168
references: Chin Med Sci J. 1995 Sep;10(3):146-50
references: 8580483
references: N Engl J Med. 1975 Jul 3;293(1):8-12
references: 1079322
references: Lancet. 2003 Aug 23;362(9384):629-39
references: 12944064
references: J Pediatr. 1982 Feb;100(2):192-6
references: 6915968
references: J Paediatr Child Health. 2004 Jan-Feb;40(1-2):28-32
references: 14718000
references: J Clin Epidemiol. 2013 Feb;66(2):124-31
references: 22406196
references: Indian J Nephrol. 2010 Apr;20(2):68-71
references: 20835318
references: Clin J Am Soc Nephrol. 2011 Jan;6(1):63-9
references: 20847092
references: Lancet. 1961 Nov 18;2(7212):1103-10
references: 13862397
references: J Pediatr. 1986 Mar;108(3):378-82
references: 3005537